We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$707M
AUM Growth
+$45.6M
Cap. Flow
-$35.7M
Cap. Flow %
-5.06%
Top 10 Hldgs %
81.61%
Holding
26
New
4
Increased
7
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$46.7M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$42.9M
3
PEN icon
Penumbra
PEN
+$34.7M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$27.5M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$49.2M
2
ABBV icon
AbbVie
ABBV
+$47.6M
3
NUVA
NuVasive, Inc.
NUVA
+$45.4M
4
PACB icon
Pacific Biosciences
PACB
+$31.1M
5
AGN
Allergan plc
AGN
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSCI
26
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-181,818
Closed -$5K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Consonance Capital Management held 26 positions worth $707M, up 6.9% from $661M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Consonance Capital Management withdrew a net $35.7M in Q2 2016, closing 4 positions and reducing 9 holdings. Its most notable exit was Merrimack Pharmaceuticals, Inc., an estimated $49.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in United Therapeutics worth $44.3M.

  • Consonance Capital Management's largest Q2 2016 buy was United Therapeutics: 418,700 shares worth $44.3M.
  • Consonance Capital Management added most to Penumbra in Q2 2016, an estimated $34.7M increase.
  • Consonance Capital Management's biggest Q2 2016 reduction was NuVasive, Inc., cutting an estimated $45.4M.
  • Consonance Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2016, selling an estimated $49.2M.
  • Consonance Capital Management's ten largest holdings make up 82% of its $707M portfolio in Q2 2016.
  • Consonance Capital Management opened 4 new positions and closed 4 in Q2 2016.
  • Consonance Capital Management's portfolio value rose 6.9% quarter-over-quarter to $707M.

Based on Consonance Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.